Physician profile
Aaron Mankin
NPI 1295168276
$52,566.34
in general payments reported to CMS, 2019-2025
40 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,125 · 2022: $7,290 · 2023: $21K · 2024: $6,658 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $8,100 · Consulting Fee: $6,512 · Travel and Lodging: $4,028 · Education: $17.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,495.00 |
| Food and Beverage | $8,099.50 |
| Consulting Fee | $6,512.00 |
| Travel and Lodging | $4,027.80 |
| Education | $17.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $21,345.19 | 2021-2025 | Erleada, Carvykti, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $20,056.47 | 2021-2025 | Lynparza |
| Pfizer INC. | $1,764.96 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $1,342.52 | 2021-2025 | Provenge |
| Sumitomo Pharma America, INC. | $1,096.76 | 2023-2025 | Gemtesa, Orgovyx |
| Ferring Pharmaceuticals INC. | $692.19 | 2024-2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $543.91 | 2021-2024 | Xiaflex |
| Laborie Medical Technologies Corp. | $530.76 | 2021-2025 | Urgent PC Neuromodulation System |
| Axonics, INC. | $448.81 | 2021-2024 | Axonics |
| Astellas Pharma US INC | $402.07 | 2021-2025 | Xtandi |
| Merck Sharp & Dohme LLC | $327.92 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Exelixis INC. | $297.25 | 2021-2024 | Cabometyx |
| Myovant Sciences INC. | $288.17 | 2021-2022 | |
| Urogen Pharma, INC. | $277.37 | 2022-2025 | Jelmyto |
| Abbvie INC. | $272.98 | 2023-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $256.29 | 2021-2025 | |
| Blue Earth Diagnostics | $249.35 | 2021-2025 | Posluma |
| Hollister Incorporated | $244.32 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $236.11 | 2021-2023 | Opdivo |
| Sun Pharmaceutical Industries INC. | $227.88 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $195.26 | 2021-2025 | Pylarify |
| Immunitybio, INC. | $194.13 | 2025 | |
| Myriad Genetic Laboratories, INC. | $172.39 | 2021-2024 | Prolaris |
| Amgen INC. | $170.80 | 2021-2023 | Xgeva |
| Tolmar Pharmaceuticals, INC. | $130.35 | 2021-2022 | |
| Boston Scientific Corporation | $104.25 | 2021-2025 | Axonics |
| Urovant Sciences INC | $99.34 | 2022 | |
| Endo USA, INC. | $80.54 | 2024 | Xiaflex |
| Tolmar, INC. | $77.70 | 2023-2025 | Eligard, Jatenzo |
| Valencia Technologies Corporation | $63.39 | 2025 | Ecoin Device Kit |
| Caris Mpi, INC. | $63.36 | 2025 | Mi Cancer Seek |
| Antares Pharma, INC. | $54.48 | 2024-2025 | Xyosted |
| Angiodynamics, INC. | $49.95 | 2021-2022 | |
| Allergan, INC. | $44.27 | 2021-2022 | |
| 180 Medical, INC. | $39.00 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $38.96 | 2023 | Fotivda |
| Olympus America INC. | $27.72 | 2025 | Itind System |
| Eisai INC. | $23.81 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.36 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.00 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Mankin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.